Study of CX-4945 in Patients With Relapsed or Refractory Multiple Myeloma

Inclusion Criteria

• Males or females at least 18 years of age
• Confirmed relapsed or refractory multiple myeloma after at least two prior lines of therapy.
• Measureable disease.
• Karnofsky Performance Status at least 60%
• Adequate liver and renal function and hematology laboratory values
• Female patients of child-bearing potential must have a negative pregnancy test.
• Signed informed consent.

Exclusion Criteria

• Treatment with systemic cancer therapy within 21 days before screening.
• Major surgery within 4 weeks or minor surgery within 2 weeks of the start of study drug.
• Grade 3 sensory neuropathy or motor neuropathy with pain
• Concurrent severe or uncontrolled medical disease.
• Active systemic fungal, bacterial, and/or viral infection.
• Difficulty with swallowing, or an active malabsorption syndrome.
• Gastrointestinal diseases including Crohn's disease or hemorrhagic coloproctitis.
• History of gastric or small bowel surgery.
• Pregnant or nursing females.